Physician profile
Robert B Cooper
NPI 1396783627
$917.77
in general payments reported to CMS, 2019-2025
15 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $38.69 · 2021: $188 · 2022: $159 · 2023: $68.83 · 2024: $28.89 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.79 | 2019-2023 | Trulance |
| Smith+Nephew, INC. | $118.39 | 2022 | |
| Salvin Dental Specialties, INC. | $104.65 | 2021 | |
| Exact Sciences Corporation | $84.80 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $75.68 | 2021-2023 | Dificid |
| Pfizer INC. | $56.36 | 2025 | |
| Mannkind Corporation | $50.00 | 2021 | |
| Abbvie INC. | $43.21 | 2025 | |
| Qol Medical, LLC | $34.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.89 | 2024 | Dupixent |
| Celltrion USA INC. | $28.07 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $24.31 | 2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $17.46 | 2023 | |
| Boston Scientific Corporation | $15.70 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $15.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.